ArticleBMJ open2021

Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial.

Bruno Francois et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.